VIP (Vasoactive Intestinal Peptide): Immunological Research Applications
Vasoactive Intestinal Peptide is a 28-amino acid neuropeptide with potent anti-inflammatory and immunomodulatory properties studied in autoimmune disease, pulmonary hypertension, and MCAS models.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide with pleiotropic biological roles spanning the autonomic nervous system, immune regulation, pulmonary physiology, and gastrointestinal function. This post synthesizes peer-reviewed research on VIP receptor biology, anti-inflammatory mechanisms, and clinical investigation — all content is provided for research reference only and does not constitute medical advice or guidance for human use.
Structural Biology and Receptor Pharmacology
The 28-Amino-Acid Neuropeptide
VIP is a member of the glucagon/secretin superfamily of neuropeptides, sharing structural homology with PACAP (pituitary adenylate cyclase-activating polypeptide), secretin, glucagon, and GIP. It was initially characterized from porcine small intestine by Said and Mutt in 1970 (Science, 1970), who named it for its pronounced vasodilatory activity in isolated blood vessel preparations.
The peptide adopts an amphipathic alpha-helical structure in solution, a conformation essential for high-affinity receptor binding. It is produced throughout the peripheral and central nervous system, with particularly high expression in neurons of the myenteric and submucosal plexuses of the gastrointestinal tract, pulmonary non-adrenergic non-cholinergic (NANC) nerve fibers, and immune cells including T lymphocytes and mast cells.
VPAC1 and VPAC2 Receptors
VIP signals primarily through two class B G protein-coupled receptors: VPAC1 (encoded by VIPR1) and VPAC2 (encoded by VIPR2), both of which couple to adenylyl cyclase via Gs proteins, producing cAMP as a primary second messenger. A third receptor, PAC1, binds PACAP with high affinity and VIP with lower affinity and is considered a PACAP-selective receptor.
VPAC1 and VPAC2 have largely overlapping but distinct tissue distributions with functional consequences. VPAC1 is the predominant receptor in lymphoid tissues, hepatocytes, lung parenchyma, and intestinal epithelium. VPAC2 shows higher expression in pancreatic islet cells, smooth muscle, and certain brain regions including the suprachiasmatic nucleus. Harmar et al. (Pharmacological Reviews, 1998) published a landmark receptor classification that formalized this nomenclature and defined key pharmacological distinctions between the subtypes.
Anti-Inflammatory Properties
Cytokine Modulation: IL-10 and TNF-alpha
The anti-inflammatory actions of VIP have been studied extensively by Delgado, Ganea, and Bhanu colleagues in a series of foundational papers spanning the early 2000s. The core finding is that VIP suppresses pro-inflammatory cytokine production (principally TNF-α, IL-6, and IL-12) by activated macrophages and dendritic cells while simultaneously promoting production of anti-inflammatory cytokines, particularly IL-10.
Delgado et al. (Journal of Clinical Investigation, 2001) demonstrated in lipopolysaccharide-stimulated peritoneal macrophages that VIP inhibited NF-κB nuclear translocation and AP-1 transcriptional activity, suppressing TNF-α production by over 60% while inducing IL-10 secretion through a VPAC1/cAMP/PKA-dependent pathway. This bidirectional effect on the inflammatory cytokine balance has positioned VIP as a research model for endogenous anti-inflammatory neuropeptide regulation.
T Cell and Regulatory Immune Modulation
VIP has also been shown to promote the differentiation of regulatory T cells (Tregs) from naive CD4+ precursors and to inhibit the Th1-polarizing cytokine environment that drives autoimmune tissue damage. Gonzalez-Rey et al. (Journal of Immunology, 2006) demonstrated in murine collagen-induced arthritis that VIP treatment expanded the Foxp3+ Treg population in draining lymph nodes and reduced synovial inflammation by shifting the Th1/Th2/Th17 balance toward an anti-inflammatory phenotype.
Pulmonary Arterial Hypertension Research
Rationale for Inhaled VIP
Pulmonary arterial hypertension (PAH) is characterized by progressive vasoconstriction and vascular remodeling of pulmonary arteries, leading to right ventricular failure. VIP's potent pulmonary vasodilatory and anti-proliferative effects on pulmonary arterial smooth muscle cells provided the rationale for investigating inhaled VIP as a targeted pulmonary vasodilator.
Preclinical work by Petkov et al. (Nature Medicine, 2003) showed that mice with VIP gene knockout spontaneously developed a PAH-like phenotype with elevated right ventricular pressures, pulmonary vascular remodeling, and exercise intolerance — findings suggesting that endogenous VIP signaling is required to maintain normal pulmonary vascular tone. This genetic evidence substantially strengthened the rationale for exogenous VIP supplementation in PAH.
Clinical Trials
Petkov et al. (Thorax, 2003) conducted a Phase II open-label study of inhaled synthetic VIP (200 µg four times daily) in eight patients with severe PAH, reporting acute reductions in mean pulmonary arterial pressure and pulmonary vascular resistance, alongside improvements in exercise capacity (6-minute walk distance) and quality of life measures over 3 months. These preliminary findings were encouraging but derived from a small, uncontrolled cohort.
Subsequent larger trials faced challenges with the short half-life of native VIP and difficulty maintaining consistent aerosol delivery. Development of longer-acting VIP analogues and optimized inhaler formulations has been an active area to address these pharmacokinetic limitations.
Mast Cell and MCAS Research
VIP in Mast Cell Biology
Mast cells express both VPAC1 and VPAC2 receptors, and VIP has documented effects on mast cell activation. Heterogeneous findings in the literature reflect the complexity of mast cell biology: at physiological concentrations VIP generally acts as a mast cell stabilizer by elevating intracellular cAMP and inhibiting degranulation, while at supra-physiological levels it has been shown to induce degranulation through receptor-independent membrane effects.
Research interest in VIP within the context of mast cell activation syndrome (MCAS) has grown, with investigators exploring whether VIP-receptor axis dysfunction may contribute to the dysregulated mast cell activation observed in MCAS patients. Afrin et al. (Diagnosis, 2016) reviewed the emerging MCAS literature and noted VIP among a panel of biomarkers and modulators warranting systematic investigation, though direct clinical evidence in MCAS populations remains limited.
Autoimmunity: Shoenfeld Laboratory Contributions
Yehuda Shoenfeld's group at Tel Aviv University has contributed a substantial body of research on VIP's role in autoimmune disease models, with particular focus on systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Gomariz et al. (Annals of the New York Academy of Sciences, 2006) summarized a series of murine autoimmune studies showing that VIP treatment reduced the severity of established collagen-induced arthritis, decreased anti-dsDNA antibody titers in lupus-prone (MRL/lpr) mice, and attenuated organ damage in experimental Sjögren's syndrome models. The proposed mechanism across these models involved VPAC receptor-mediated suppression of Th17 cells and inflammatory macrophages, alongside expansion of Treg populations.
These findings have fueled interest in VIP-based immunomodulatory peptide design, with several groups investigating truncated and modified VIP analogues that retain anti-inflammatory activity while improving pharmacokinetic stability.
Gastrointestinal Role
Gut Motility and Secretion
VIP was originally characterized as a neuromodulator of gastrointestinal function, and its enteric nervous system roles remain among the best-validated aspects of its biology. As a non-adrenergic non-cholinergic (NANC) neurotransmitter in the myenteric plexus, VIP mediates inhibitory postjunctional responses that relax intestinal smooth muscle, regulate sphincter tone, and coordinate peristaltic reflexes.
Furness (Autonomic Neuroscience, 2012) reviewed the role of VIP in enteric neural circuitry, noting that VIP-immunoreactive neurons constitute the primary inhibitory motor neurons to the circular muscle layer throughout the small and large intestine, functioning alongside nitric oxide as the principal NANC inhibitory transmitters. Impaired VIP signaling in the enteric nervous system has been implicated in dysmotility disorders including achalasia and Hirschsprung's disease.
Intestinal Secretion and Epithelial Function
Beyond smooth muscle, VIP stimulates intestinal epithelial chloride secretion through VPAC1-mediated cAMP elevation, effects that contribute to the profuse watery diarrhea characteristic of VIPoma syndrome — a rare neuroendocrine tumor that secretes VIP ectopically.
For further mechanistic context on related neuropeptide signaling, see the peptide library for related compounds in this database.
See also: VIP compound library entry
All content on ClinicalPeptide.org is intended exclusively for research reference. No content constitutes medical advice, clinical guidance, or recommendations for human use.